Medtronic Plc (NYSE:MDT) on Tuesday reported strong second-quarter 2026 results.The company’s sales reached $8.96 billion, surpassing the consensus estimate of$8.87 billion. This marks a 6.6% increase year-over-year, with organic growth of 5.5%. Adjusted earnings of $1.36 per share also beat expectations of$1.31."…Overall, procedure volumes and our end markets are robust, and we're executing well across the business," said Geoff Martha, Medtronic chairman and CEO.Medtronic raised its fiscal year 2026 orga ...